MedTrace Logo

Induction of Fibrosis Regression on Patients With Chronic Hepatitis B Infection

NCT01341106 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 7

Last updated 2015-09-23

No results posted yet for this study

Summary

This study will examine whether 12 month treatment with entecavir(Baraclude®) has an effect on changes of liver stiffness measurement (LSM) and of hyaluronan measurement in patients with chronic hepatitis B infection.

Conditions

  • Hepatitis B, Chronic
  • Liver Fibrosis

Interventions

DRUG

Treatment with entecavir(Baraclude®)

Patient will be daily treated with 1 tablet of entecavir per oral

Sponsors & Collaborators

  • Hannover Medical School

    collaborator OTHER

  • RWTH Aachen University

    lead OTHER

Principal Investigators

  • Christian Trautwein, Professor MD · Department of Internal Medicine III, University Hospital Aachen

Study Design

Allocation
NA
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2015-01-31
Completion
2015-04-30

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01341106 on ClinicalTrials.gov